- Source type
- Article
- Access type
- Publisher
- Publisher
- Reuters
- Date
- 2026-01-07
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
RNA Medicine Helped Some Hepatitis B Patients Reach Functional Cure
Roles: Background
Show section-level references
- Bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, helped a subset of Phase 3 trial participants reach functional cure, meaning virus markers stayed suppressed after treatment stopped. This is not full viral eradication and not yet an approved therapy.Independent trial-result reporting for corroboration.
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: PROPEL 3 study NCT06164951
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
AP: bepirovirsen and chronic hepatitis B functional cure reporting
Independent patient-facing reporting; not a primary trial or regulatory source.
- Trust score
- 60
- Publisher
- Associated Press
- Access
- Publisher
- Usage
- 1 connection
Wall Street Journal: GSK hepatitis B drug candidate trial report
Independent business-health reporting; avoid using headline cure language unbounded.
- Trust score
- 60
- Publisher
- The Wall Street Journal
- Access
- Publisher
- Usage
- 1 connection
Capital B News: A New Chapter for Sickle Cell Care Begins in Louisiana
Canonical source record for the republished rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.
- Trust score
- 60
- Publisher
- Capital B News
- Access
- Publisher
- Usage
- 0 connections
HCPLive: tulisokibart Phase 3 UC endpoints
Canonical source record for the republished rapid brief tulisokibart-ulcerative-colitis-phase-3-remission.
- Trust score
- 60
- Publisher
- HCPLive
- Access
- Publisher
- Usage
- 1 connection
Intellia Therapeutics: positive Phase 3 HAELO results
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Intellia Therapeutics
- Access
- Publisher
- Usage
- 1 connection